154 related articles for article (PubMed ID: 38319286)
1. Oncogenic GNAS Uses PKA-Dependent and Independent Mechanisms to Induce Cell Proliferation in Human Pancreatic Ductal and Acinar Organoids.
Desai R; Huang L; Gonzalez RS; Muthuswamy SK
Mol Cancer Res; 2024 May; 22(5):440-451. PubMed ID: 38319286
[TBL] [Abstract][Full Text] [Related]
2. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism.
Patra KC; Kato Y; Mizukami Y; Widholz S; Boukhali M; Revenco I; Grossman EA; Ji F; Sadreyev RI; Liss AS; Screaton RA; Sakamoto K; Ryan DP; Mino-Kenudson M; Castillo CF; Nomura DK; Haas W; Bardeesy N
Nat Cell Biol; 2018 Jul; 20(7):811-822. PubMed ID: 29941929
[TBL] [Abstract][Full Text] [Related]
3. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
4. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
5. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
[TBL] [Abstract][Full Text] [Related]
6. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway.
Kawabata H; Ono Y; Tamamura N; Oyama K; Ueda J; Sato H; Takahashi K; Taniue K; Okada T; Fujibayashi S; Hayashi A; Goto T; Enomoto K; Konishi H; Fujiya M; Miyakawa K; Tanino M; Nishikawa Y; Koga D; Watanabe T; Maeda C; Karasaki H; Liss AS; Mizukami Y; Okumura T
J Gastroenterol; 2022 Mar; 57(3):208-220. PubMed ID: 35018527
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
[TBL] [Abstract][Full Text] [Related]
9. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
[TBL] [Abstract][Full Text] [Related]
10. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
11. Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression.
Ferreira RMM; Sancho R; Messal HA; Nye E; Spencer-Dene B; Stone RK; Stamp G; Rosewell I; Quaglia A; Behrens A
Cell Rep; 2017 Oct; 21(4):966-978. PubMed ID: 29069604
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic GNAS uses PKA-dependent and independent mechanisms to induce cell proliferation in human pancreatic ductal and acinar organoids.
Desai R; Muthuswamy S
bioRxiv; 2023 Jan; ():. PubMed ID: 36789419
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
[TBL] [Abstract][Full Text] [Related]
14. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
15. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes.
Komatsu H; Tanji E; Sakata N; Aoki T; Motoi F; Naitoh T; Katayose Y; Egawa S; Unno M; Furukawa T
PLoS One; 2014; 9(2):e87875. PubMed ID: 24498386
[TBL] [Abstract][Full Text] [Related]
16. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
17. McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation - a case report.
Gaujoux S; Pasmant E; Silve C; Mehsen-Cetre N; Coriat R; Rouquette A; Douset B; Prat F; Leroy K
Medicine (Baltimore); 2019 Dec; 98(50):e18102. PubMed ID: 31852070
[TBL] [Abstract][Full Text] [Related]
18. KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas.
Tampakis A; Tampaki EC; Posabella A; Zettl A; Kouraklis G; von Flüe M; Guenin MO
Pancreas; 2017 Jan; 46(1):e5-e7. PubMed ID: 27977634
[No Abstract] [Full Text] [Related]
19. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
[TBL] [Abstract][Full Text] [Related]
20. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
